Rare Infectious Disease News
Advertisement
Spotlight On
Anthrax
Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis
Prevalence
Age of Onset
ICD-10
A22
Inheritance
This condition does not appear to have a clear pattern of inheritance.
5 Facts you should know
FACT
Can occur in four forms: skin, lungs, intestinal, and injection.
FACT
Symptom onset occurs between one day to over two months after the infection is contracted.
FACT
Skin infections represent more than 95% of cases - without treatment, the risk of death from skin anthrax is 25%.
FACT
Does not typically spread directly between people.
FACT
Human anthrax is most common in Africa and central and southern Asia.
Interest over time
Google searches
Common signs & symptoms
Current treatments
Raxibacumab
(Brand name: Abthrax) Manufactured by Human Genome Sciences, Inc.
FDA-approved indication: Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalation anthrax when alternative therapies are not available or are not appropriate.
obiltoxaximab
(Brand name: Anthim) Manufactured by Elusys Therapeutics, Inc.
FDA-approved indication: Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
anthrax immune globulin (human)
(Brand name: Anthrasil) Manufactured by Emergent Biosolutions
FDA-approved indication: Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs
Top Clinical Trials
| Title | Description | Phases | Status | Interventions | More Information |
|---|---|---|---|---|---|
| A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults | The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1010. BW-1010 is a nanoemulsion adjuvanted recombinant protein (rPA) that would protect against fatal outcome resulting from exposure to anthrax. | Phase 1 | Active, not recruiting | Biological: BW-1010: 50 µg - sprayer - IN|Biological: BW-1010: 50 µg - pipette - IN|Biological: BW-1010: 100 µg - sprayer - IN|Biological: BW-1010: 100 µg - pipette - IN|Biological: Saline (Placebo) - sprayer - IN|Biological: Saline (Placebo) - pipette - IN|Biological: BioThrax (positive control) - SC | More Info |
| Anthrax AV7909 Liquid vs Lyophilized | This is a randomized, parallel-group, double-blind, Phase 1 study designed to assess safety, tolerability and immunogenicity 2 formulations of adjuvanted anthrax vaccine (AV7909), lyophilized and liquid. | Phase 1 | Not yet recruiting | Biological: AV7909 | More Info |
Top Treatments in Research
| Agent | Class/Mechanism of Action | Development Status | Company | Clinical Studies | More Information |
|---|---|---|---|---|---|
| BW-1010 | BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the immune system via the nasal mucosa, with Porton Biopharma Limited’s (PBL) recombinant protective antigen (rPA) for anthrax. | Phase 1 | BlueWillow Biologics. Porton Biopharma Ltd. | More Info | More Info |
| AV7909 | This is a randomized, parallel-group, double-blind, Phase 1 study designed to assess safety, tolerability and immunogenicity 2 formulations of adjuvanted anthrax vaccine (AV7909), lyophilized and liquid. | Phase 1 | AV709 is being evaluated by National Institute of Allergy and Infectious Diseases (NIAID) | More Info | More Info |